HSIC — Henry Schein, Inc.
Is HSIC overbought or oversold? Here is the current MarketMoodz read.
Henry Schein, Inc. (HSIC) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Distribution) last closed at $84.96. The rating moved from Neutral to Oversold on November 16, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$84.96
- Last changeMoved from Neutral to Oversold on November 16, 2026
- SectorHealthcare
- IndustryMedical Distribution
See all oversold Healthcare stocks →
AI analysis
Henry Schein combines a diversified, recurring distribution business across dental, medical and animal health with growing exposure to specialty care services; this creates a stable cash profile while offering modest growth upside from specialty channels and digital initiatives. Current sector flows favor defensive healthcare exposure, which can support near-term stability. Key risks include regulatory/political scrutiny of vertically integrated healthcare, competitive pressure from larger distributors and e-commerce entrants, reimbursement dynamics that affect provider purchasing, and recent corporate disclosure that adds short-term uncertainty. The outlook points to steady cash generation and selective growth catalysts, but meaningful upside depends on successful specialty expansion and margin preservation.
Key factors
- Diversified distribution footprint across dental, medical and animal health provides stable, recurring revenue streams and resilience in mixed macro environments
- Exposure to specialty care and biopharma service flows which could support sustained order volumes and higher-margin distribution over time
- Defensive investor interest in large-cap healthcare names supports relative stability during risk-off windows and may reduce near-term volatility
- Established logistics, supplier relationships and digital/e-commerce initiatives that improve customer retention and operational efficiency
- Moderate free-cash-generation profile historically enables share buybacks and opportunistic M&A to supplement organic growth
Risks
- Regulatory and political pressure on vertically integrated healthcare could create readthrough volatility or policy risk for distributors and channel participants
- Competition from larger distributors, specialty pharmacies and e-commerce players could compress gross margins and market share
- Reimbursement changes or Medicare/insurer dynamics affecting provider demand for consumables and equipment
- Execution risk from integrating specialty service offerings and converting distributor mix without eroding margins
- Recent negative 8-K filing introduces near-term uncertainty around corporate developments or disclosures
See today's live rating, score and targets
Members see the live hourly rating for HSIC — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.